

# Marrone Bio Innovations

14:35 01 Oct 2019

## Marrone Bio's crop biofungicide Stargus approved for use in Mexico

Marrone Bio Innovations Inc (NASDAQ:MBII) announced Tuesday that its novel *Bacillus* biofungicide, marketed in the US as Stargus for specialty crops, has been approved for use in Mexico.

Stargus will be used in Mexico to control downy mildews, late blight and a broad range of other plant-related diseases on zucchini, squash, chayote, melon, cucumber, watermelon and potato crops, according to a statement.

Stargus will be available to Mexican farmers to utilize on their own crops in the upcoming growing season, Marrone Bio said.

### READ: Marrone Bio closes its acquisition of Finland-based Pro Farm Technologies OY

The US imported more than \$12 billion in fruits and vegetables from Mexico in 2016, making America's southern neighbor the largest foreign supplier of vegetables and fruits in the US.

The active ingredient in Stargus, recognized by Mexico's Ministry of Health as a reduced risk biological pesticide due to its low toxicity profile, is a new strain of *Bacillus amyloliquefaciens* that has been recently reclassified as *Bacillus nakamurai* by taxonomists.

Stargus is unique in its high performance on downy mildews, white molds, *Fusarium* and *Botrytis* gray mold, which are particularly difficult to control.

Marrone Bio said the market for effective and environmentally friendly products is growing at a rate of 10-20% per year.

When integrated into crop production and pest-management programs, biologicals - including Stargus - can offer farmers higher-quality crops and better yields than conventional programs alone, the company noted.

"As a major fresh fruit and vegetable producer and our nation's largest supplier of seasonal crops, Mexico is a critical market for MBI to enter with innovative products like Stargus," said CEO Dr Pamela Marrone.

"With the Canadian approval of Stargus earlier this year and this recent approval in Mexico, MBI has significantly expanded our international reach with key US trading partners. This is a real growth opportunity for Marrone Bio, and we are thrilled that Stargus is approved and will be ready to use in the key upcoming Mexican growing season."

Marrone Bio, based in Davis, California, provides bio-based pest management and plant health products for the US and international agricultural and water markets.

Contact the author: [patrick@proactiveinvestors.com](mailto:patrick@proactiveinvestors.com)

**Price:** 1.07

**Market Cap:** \$159.57 m

### 1 Year Share Price Graph



### Share Information

**Code:** MBII

**Listing:** NASDAQ

52 week	High	Low
	1.72	0.6104

**Sector:** Agribusiness

**Website:** [www.marronebioinnovations.com](http://www.marronebioinnovations.com)

### Company Synopsis:

*Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth company leading the movement to more a sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that help customers operate more sustainably while increasing their return on investment.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Follow him on Twitter @PatrickMGraham

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Marrone Bio Innovations named herein, including the promotion by the Company of Marrone Bio Innovations in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).